Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 2017
October 17 2017 - 9:15AM
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global,
high-growth diagnostics company focused on developing and
commercializing proprietary tests for the management of underserved
immune-regulated conditions, today announced that it plans to
release third quarter 2017 financial results prior to market open
on Tuesday, October 31, 2017. Dr. Peter Wrighton-Smith, Chief
Executive Officer, and Rick Altieri, Chief Financial Officer, will
host a conference call to review the Company's results at 8:00 a.m.
Eastern Time the same day. The call will be concurrently webcast.
To listen to the conference call on your telephone, please dial
(855) 363-5047 for United States callers and +1 (484) 365-2897 for
international callers and reference confirmation code 99539511,
approximately ten minutes prior to start time. To access the
live audio webcast or subsequent archived recording, visit the
Investor Relations section of Oxford Immunotec's website at
www.oxfordimmunotec.com. The replay will be available on the
Company's website for approximately 60 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics
company focused on developing and commercializing proprietary tests
for the management of underserved immune-regulated
conditions. The Company's first product is the
T-SPOT®.TB test, which is used to test for tuberculosis
infection. The T-SPOT.TB test has been approved for sale
in over 50 countries, including the United States, where it has
received pre-market approval from the Food and Drug Administration,
Europe, where it has obtained a CE mark, as well as Japan and
China. The Company's second product line is a range of assays
for tick-borne diseases, such as Lyme disease, obtained through the
acquisitions of Imugen and Immunetics. Also obtained through
the acquisitions is the Company's third product line focused on
screening for Babesia in donated blood, for which the Company is
currently seeking FDA licensure. The T-SPOT.CMV test and the
T-SPOT.PRT test are pipeline products as part of the Company's
fourth intended product line focused on the transplantation
market. In addition to these four product lines, the Company
has additional active development programs in other
immune-regulated conditions. The Company is headquartered
near Oxford, U.K. and in Marlborough, Mass. Additional
information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford
Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
CONTACT:
For Media and Investor Inquiries: Karen Koski
Head of Strategy and Investor Relations Oxford Immunotec Tel: +1
(508) 556-1377 kkoski@oxfordimmunotec.com
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From Sep 2023 to Sep 2024